PAH Market Heats Up: New Approvals For Actelion, United Therapeutics

With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015